Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.

doi:10.1182/bloodadvances.2023011106

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.

Blood advances - 23 Jan 2024

Jimenez-Chillon Carlos, Othman Jad, Taussig David, Jimenez-Vicente Carlos, Martinez-Roca Alexandra, Tiong Ing Soo, Jain Manish, Aries James, Cakmak Seda, Knapper Steven, Kristensen Daniel Tuyet, Murthy Vidhya, Galani Joy Zacharoula, Kallmeyer Charlotte, Ngu Loretta, Veale David, Bolam Simon, Orfali Nina, Parker Anne, Manson Cara, Parker Jane, Erblich Thomas, Richardson Deborah, Mokretar Katya, Potter Nicola, Overgaard Ulrik Malthe, Roug Anne Stidsholt, Wei Andrew H, Esteve Jordi, Jädersten Martin, Russell Nigel, Dillon Richard

Abstract excerpt

ABSTRACT: Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular failure with venetoclax...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Recurrence

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 38039513
DOI: 10.1182/bloodadvances.2023011106
PMCID: PMC10788851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.PMID 38039513Read ↗

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.Semantic proximity Read ↗

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.Semantic proximity Read ↗

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO studySemantic proximity Read ↗

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesSemantic proximity Read ↗

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.